• By ICR Secretariat
  • Posted Wednesday, March 15, 2017

FDA reveals recommendations for generics and biosimilars

http://www.fdanews.com/articles/180802-fda-proposes-eight-month-review-of-priority-generics-plans-for-wave-of-biosimilars

The FDA officially unveiled its recommendations for the second generation of user fee agreements covering generics and biosimilars, with commitments to eight-month reviews of priority generics.